Adherence to disease-modifying drugs in patients with multiple sclerosis: A consensus statement from the middle east MS advisory group

International Journal of Neuroscience

Volumn 120, Issue 4, 2010, Pages 273-279

  Yamout, Bassem I ^a   Dahdaleh, Maurice ^b   Jumah, Mohammed Ali Al ^c   Al Shammri, Suhail ^d   Sharoqi, Isa Al ^e   Al Tahan, Abdel Rahman ^f   Bohlega, Saeed ^g   Deleu, Dirk ^h   Inshasi, Jihad ⁱ   Khalifa, Ahmad ^j   Szlics, Miklos ^k  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Arab Medical Centre   (Jordan)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d KUWAIT UNIVERSITY   (Kuwait)

^e Neurology Unit   (Bahrain)

^f KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^h HAMAD MEDICAL CORPORATION   (Qatar)

ⁱ RASHID HOSPITAL   (United Arab Emirates)

^j Damascus Hospital   (Syrian Arab Republic)

^k JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Adherence; Consensus; Disease modifying drugs; Middle East; Multiple sclerosis; Recommendations

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

ADVISORY COMMITTEE; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; MEDICAL SPECIALIST; MIDDLE EAST; MULTIPLE SCLEROSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; CONSENSUS; DISABILITY EVALUATION; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE EAST; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 77950788260     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207450903541087     Document Type: Review

References (48)

1. Al-Sabbagh, A., et al. (2008, June 9). Medication gaps in diseasemodifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database. Poster session 321 presented at the 18th Meeting of the ENS, Poster 321.
2. Arnason, B. G. (2005). Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis. Journal of Neurology, 252(Suppl. 3), iii28-iii33.
3. Atkinson,M. J., et al. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes, 2, 12.
4. Bashir, K., et al. (2002). Optimizing immunomodulatory therapy for MS patients. International Journal of MS Care, 4, 3-7.
5. Bellary, S., & Barnett, A. H. (2006). Inhaled insulin (Exubera): Combining efficacy and convenience. Diabetes & Vascular Disease Research, 3, 179-185.
6. Brown, M. G., et al. (2007). How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, 69, 1498-1507.
7. Buhse, M. (2006). Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis. The Journal of Neuroscience Nursing, 38, 222-226.
8. Clanet,M., et al. (2004). Interferon beta-1a in relapsing multiple sclerosis: Four-year extension of the European IFNbeta-1a Dose-Comparison Study. Multiple Sclerosis, 10, 139-144.
9. Cohen, B. A. (2006). Adherence to disease-modifying therapy for multiple sclerosis. International Journal of MS Care, 8(Suppl. 1), 32-37.
10. Cohen, B. A., & Rieckmann, P. (2007). Emerging oral therapies for multiple sclerosis. International Journal of Clinical Practice, 61, 1922-1930.
11. Conlin, P. R., et al. (2001). Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clinical Therapeutics, 23, 1999-2010.
12. Cooper, I. M. (1996). Morphine for postoperative analgesia. A comparison of intramuscular and subcutaneous routes of administration. Anaesthesia and Intensive Care, 24, 574-578.
13. Costello, K., et al. (2008). Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape Journal of Medicine, 10, 225.
14. Cox, D., & Stone, J. (2006).Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. The Journal of Neuroscience Nursing, 38, 167-171.
15. Cramer, J. A., et al. (2006). Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurologica Scandinavica, 113, 156-162.
16. Dupclay, L., Jr., & Doyle, J. (2002). Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. The American Journal of Managed Care, 8, S335-S340.
17. Fallowfield, L., et al. (2006). Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Annals of Oncology, 17, 205-210.
18. Freedman, M. S., et al. (2004). Treatment optimization in multiple sclerosis. The Canadian Journal of Neurological Sciences, 31, 157-168.
19. Haynes, R. B., Yao, X., Degani, A., Kripalani, S., Garg, A., McDonald, H. P. (2005). Interventions to enhance medication adherence. Cochrane Database Systematic Reviews, CD000011.
20. Hutchinson, M. (2005). Treatment adherence: What is the best that can be achieved? International MS Journal, 12, 73.
21. IFNB MS Study Group. (1995). Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology, 45, 1277-1285.
22. Johnson, K. P., et al. (2000). Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Mmultiple Ssclerosis Sstudy Ggroup. Multiple Sclerosis, 6, 255-266.
23. Jordy, S. S., et al. (2008). Immunomodulator therapy migration in relapsing remitting multiple sclerosis: A study of 152 cases. Arquivos de Neuro-Psiquiatria, 66, 11-14.
24. Kappos, L., et al. (2006). Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology, 67, 944-953.
25. Kruk, M. E., & Schwalbe, N. (2006). The relation between intermittent dosing and adherence: Preliminary insights. Clinical Therapeutics, 28, 1989-1995.
26. Lee, W. C., et al. (2006). Prevalence and economic consequences of medication adherence in diabetes: A systematic literature review. Managed Care Interface, 19, 31-41.
27. Liu, G., et al. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology, 15, 110-115.
28. Lugaresi, A., et al. (2008). Safety and tolerability in relapsingremitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: The CoSa study. Clinical Neuropharmacology, 31, 167-172.
29. Meletiche, D., et al. (2008a, June 9). Association between adherence with multiple sclerosis disease-modifying therapy and severe relapses using 3 measures of medication adherence. Poster session 717 presented at the 18th Meeting of the ENS.
30. Meletiche, D., et al. (2008b, June 10). Relationship between severe relapses and adherence to disease-modifying therapy in multiple sclerosis patients. Poster session 826 presented at the 18th Meeting of the ENS.
31. Milanese, C., et al. (2003). A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: Different response in drop-outs and treated patients. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 1689-1692.
32. Mohr, D. C., et al. (1996). Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: Relationship to adherence to treatment. Multiple Sclerosis, 2, 222-226.
33. Mohr,D. C., et al. (1999). Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Multiple Sclerosis, 5, 192-197.
34. Mohr, D. C., et al. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125-132.
35. Mohr, D. C., et al. (2002). Teaching patients to self-inject: Pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. Journal of Behavior Therapy and Experimental Psychiatry, 33, 39-47.
36. O'Rourke, K. E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns. Multiple Sclerosis, 11, 46-50.
37. Partridge, A. H., et al. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94, 652-661.
38. Patten, S. B., et al. (2005). The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Multiple Sclerosis, 11, 175-181.
39. Portaccio, E., et al. (2008). Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. European Neurology, 59, 131-135.
40. Reginster, J. Y., et al. (2006). Adherence, patient preference and dosing frequency: Understanding the relationship. Bone, 38, S2-S6.
41. Rio, J., et al. (2005). Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11, 306-309.
42. Rovaris, M., et al. (2006). Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurology, 5, 343-354.
43. Sokol, M. C., et al. (2005). Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care, 43, 521-530.
44. Stone, V. E. (2001). Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases, 33, 865-872.
45. Tremlett, H. L., & Oger, J. (2003). Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology, 61, 551-554.
46. Williams, M., et al. (2007). The mean levels of adherence and factors contributing to non-adherence in patients on highly active antiretroviral therapy. The West Indian Medical Journal, 56, 270-274.
47. Wilson, D. M., et al. (1985). Subcutaneous versus intramuscular growth hormone therapy: Growth and acute somatomedin response. Pediatrics, 76, 361-364.
48. World Health Organization. (2003). Adherence to Long-term Therapies. Evidence for Action. Geneva.